Zonisamide

  • I. E. Leppik
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 138)

Abstract

Zonisamide is a synthetic 1,2-benzisoxazole derivative (1,2-benzisoxazole-3-methanesulphonamide). The anticonvulsant properties of zonisamide were not predicted from its chemistry; rather they were discovered by routine screening of various 1,2-benzisoxazole derivatives. Its formula is C8H8N2O3S, and its molecular weight is 212. It has a pK a of 9.66, so that its water solubility is dependent on the pH. Below a pH of 8, it has a solubility of only 0.8mg/ml, but it has a marked increase in solubility as the pH increases into the alkaline range. Although zonisamide is quite soluble in acetone it is much less soluble in methanol, ethanol, ether and chloroform. Its synthesis was first accomplished in 1972 by Uno et al. (1976).

Keywords

Placebo Fatigue Amide Oxalate Monit 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berent S, Sackellares JC, Giordani B, Wagner JG, Donofrio PD, Abou-Khalil B (1987) Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 28:61–67PubMedCrossRefGoogle Scholar
  2. Browne TR, Leppik IE, Penry JK, Dean C, Buchanan RA (1998) Zonisamide efficacy in long term studies. Epilepsia (in press)Google Scholar
  3. Buchanan RA, Bockbrader HN, Chang T, Sedman AJ (1996) Single-and multiple-dose pharmacokinetics of zonisamide. Epilepsia 37 [Suppl 5]: 172Google Scholar
  4. Charles CL, Stoesz L, Tollefson G (1990) Zonisamide-induced mania. Psychosomatics 31:214–217PubMedGoogle Scholar
  5. Fromm GH, Shibuya T, Terrence CF (1987) Effect of zonisamide (CI-912) on a synaptic system model. Epilepsia 28:673–679PubMedCrossRefGoogle Scholar
  6. Furuno K, Oishi R, Gomita Y, Eto K (1994) Simple and sensitive assay of zonisamide in human serum by high-performance liquid chromatography using a solid-phase extraction technique. J Chromatogr B Biomed Appl 656:456–459PubMedCrossRefGoogle Scholar
  7. Hashimoto Y, Odani A, Tanigawara Y, Yasuhara M, Okuno T, Hori R (1994) Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients. Biol Pharm Bull 17:323–326PubMedCrossRefGoogle Scholar
  8. Henry T, Leppik IE, Gumnit RJ, Jacobs M (1988) Progressive myoclonus epilepsy treated with zonisamide. Neurology 38:928–931PubMedGoogle Scholar
  9. Hori M, Ito T, Yoshida K, Shimizu M (1979) Effect of anticonvulsants on spiking activity induced by cortical freezing in cats. Epilepsia 20:25–36PubMedCrossRefGoogle Scholar
  10. Ito T, Hori M, Yoshida K, Shimizu M (1979) Effect of anticonvulsants on experimental cortical epilepsy induced by tungstic acid gel in rats. Arch Int Pharmacodyn 241:287–299PubMedGoogle Scholar
  11. Ito T, Hori M, Masuda Y, Yoshida K, Shimizu M (1980) 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Electroencephalograpnic profile. Arzneimittelforsch 30:603–609PubMedGoogle Scholar
  12. Ito T, Yamaguchi T, Miyazaki H et al. (1982) Pharmacokinetic studies of AD-810, a new antiepileptic compound, Phase I trials. Arzneimittelforsch 32:1581–1586PubMedGoogle Scholar
  13. Ito T, Hori M, Kadokawa T (1986) Effects of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. Epilepsia 27:367–374PubMedCrossRefGoogle Scholar
  14. Juergens U (1987) Simultaneous determination of zonisamide and nine other antiepileptic drugs and metabolites in serum. A comparison of microbore and conventional high-performance liquid chromatography. J Chromatogr 385:233–240PubMedCrossRefGoogle Scholar
  15. Kaibe K, Nishimura S, Ishii H, Sunahara N, Naruto S, Kurooka S (1990) Competitive binding enzyme immunoassay for zonisamide, a new antiepileptic drug, with selected paired-enzyme labeled antigen and antibody. Clin Chem 36:24–27Google Scholar
  16. Kaneko S, Hayashimoto A, Niwayama H, Fukushima Y (1993) Effects of zonisamide on serum levels of phenytoin and carbamazepine. Jpn J Epilepsy Soc 11:31–35 (in Japanese)Google Scholar
  17. Kimura S (1994) Zonisamide-induced behavior disorder in two children. Epilepsia 35:403–405PubMedCrossRefGoogle Scholar
  18. Kimura M, Tanaka N, Kimura Y, Miyake K, Kitaura T, Fukuchi H (1992) Pharmacokinetic interaction of zonisamide in rats; effect of other antiepileptics on zonisamide. J Pharmacobio Dyn 15:631–639PubMedGoogle Scholar
  19. Kimura M, Tanaka N, Kimura Y, Miyake K, Kitaura T, Fukuchi H (1993) Pharmacokinetic interaction of zonisamide in rats. Effect of zonisamide on other antiepileptics. Biol Pharm Bull 16:722–725PubMedCrossRefGoogle Scholar
  20. Kondo T, Kaneko S, Amano Y, Egawa I (1996) Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 37:1242–1244PubMedCrossRefGoogle Scholar
  21. Kumagai N, Seki T, Yamawaki H et al. (1991) Monotherapy for childhood epilepsies with zonisamide. Jpn J Psychiatr Neurol 45:357–359Google Scholar
  22. Kyllerman M, Ben-Menachem E (1996) Long-term treatment of progressive myoclonic epilepsy syndromes with zonisamide and n-acetylcysteine. Epilepsia 37 [Suppl 5]:172Google Scholar
  23. Leppik IE, Willmore LJ, Homan RW et al. (1993) Efficacy and safety of znoisamide: results of a multicenter study. Epilepsy Res 14:165–173PubMedCrossRefGoogle Scholar
  24. Masuda Y, Karasawa T, Shiraishi Y, Hori M, Yoshida K, Shimizu M (1980) 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneimittelforsch 30:477–483PubMedGoogle Scholar
  25. Matsumoto K, Miyazaki H, Fujii T, Kagemoto A, Maeda T, Hashimoto M (1983) Absorption, distribution and excretion of 3-(sulfamoyl[14C]-methyl)-1,2-benzisoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in man. Arzneimittelforsch 33:961–968PubMedGoogle Scholar
  26. Matsumoto K, Miyazaki H, Fujii T, Miyazaki H, Hashimoto M (1989) Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction. Chem Pharm Bull 37:2807–2810PubMedGoogle Scholar
  27. McJilton J, DeToledo J, DeCerce J, Huda S, Abubakr A, Ramsay RE (1996) Cotherapy of lamotrigine/zonisamide results in significant elevation of zonisamide levels. Epilepsia 37 [Suppl 5]:173Google Scholar
  28. Mimaki T, Tanoue H, Matsunaga Y, Miyazaki H, Mino M (1994) Regional distribution of [14C]zonisamide in rat brain. Epilepsy Res 17:223–236CrossRefGoogle Scholar
  29. Naito H, Itoh N, Matsui N, Eguchi T (1988) Monitoring plasma concentrations of zonisamide and clnazepam in an epileptic attempting suicide by an overdose of the drugs. Curr Ther Res 43:463–467Google Scholar
  30. Nakasa H, Komiya M, Ohmori S, Kitada M, Rikihisa T, Kanakubo Y (1992) Formation of reductive metabolite, 2-sulfamoylacetylphenol, from zonisamide in rat liver microsomes. Res Commun Chem Pathol Pharmacol 77:31–41PubMedGoogle Scholar
  31. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kitada M (1993a) Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Dispos 21:777–781PubMedGoogle Scholar
  32. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M (1993b) Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 44:216–221PubMedGoogle Scholar
  33. Nakasa H, Ohmori S, Kitada M (1996) Formation of 2-sulphamoylacetylphenol from zonisamide under aerobic conditions in rat liver microsomes. Xenobiotica 26:495–501PubMedCrossRefGoogle Scholar
  34. Ojemann LM, Shastri RA, Wilensky AJ, Friel PN, Levy RH, McLean JR, Buchanan RA (1986) Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patents on carbamazepine or phenytoin monotherapy. Ther Drug Monit 8:293–296PubMedCrossRefGoogle Scholar
  35. Padgett CS, Bergen DC, French JA, Buchanan RA (1997) Renal calculi associated with zonisamide. Epilepsia 37 [Suppl 5]:173Google Scholar
  36. Page JG, Kochak GM, Polvino WJ, Buchanan RA (1996) Multiple dose zonisamide metabolism. Epilepsia 37 [Suppl 5]:172Google Scholar
  37. Rock DM, Macdonald RL, Taylor CP (1989) Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 3:138–143PubMedCrossRefGoogle Scholar
  38. Sackellares JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, AAsved-Hoyt K (1985) Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 26:206–211PubMedCrossRefGoogle Scholar
  39. Schmidt D, Jacob R, Loiseau P et al. (1993) Zonisamide for add-on treatment of refractory partial epielpsy: a European double blind trial. Epilepsy Res 15:67–73PubMedCrossRefGoogle Scholar
  40. Seino M, Miyazaki H, Ito T (1991) Zonisamide. In: Pisani F, Perucca E, Avanzini G, Richens A (eds) New antiepileptic drugs (Epilepsy Res Suppl 3). Elsevier, New York, p. 169Google Scholar
  41. Seino M, Naruto S, Ito T, Miyazaki H (1995) Other antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York, p. 1011Google Scholar
  42. Shinoda M, Akita M, Hasegawa M, Hasegawa T, Nabeshima T (1996) The necessity of adjusting the dosage of zonisamide when coadministered with other antiepileptic drugs. Biol Pharm Bull 19:1090–1092PubMedCrossRefGoogle Scholar
  43. Stiff DD, Zemaitis MA (1990) Metabolism of the anticonvulsant agent zonisamide in the rat. Drug Metab Dispos 18:888–894PubMedGoogle Scholar
  44. Stiff DD, Robicheau JT, Zemaitis MA (1992) Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative. Xenobiotica 22:1–11PubMedCrossRefGoogle Scholar
  45. Sugihara K, Kitamura S, Tatsumi K (1996) Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Dispos 24:199–202PubMedGoogle Scholar
  46. Suzuki S, Kawakami K, Nishimura S et al. (1992) Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 12:21–27PubMedCrossRefGoogle Scholar
  47. Tasaki K, Minami T, Ieiri I, Ohtsubo K, Hirakawa Y, Ueda K, Higuchi S (1995) Drug interactions of zonisamide with phenytoin and sodum valproate: serum concentrations and protein binding. Brain Develop 17:182–185CrossRefGoogle Scholar
  48. Taylor CP, McLean JR, Bockbraer HN et al. (1986) Zonisamide (AD-810, CI-912). In: Meldrum BS, Porter RJ (eds) New anticonvulsant drugs. John Libbey, London, pp. 277–294Google Scholar
  49. Uno H, Kurokawa M, Natsuka K, Yamato Y, Nishimura H (1976) Studies on 3-substituted 1,2-benzisoxazole derivatives. Chem Pharm Bull 24:632–643Google Scholar
  50. Wada Y, Hasegawa H, Okuda H, Yamaguchi N (1990) Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex. Brain Dev 12:206–210PubMedGoogle Scholar
  51. Wagner JG, Sackellares JC, Donofrio PD, Berent S, Sakmer E (1984) Nonlinear pharmacokinetics of CI-912 in adult epileptic patients. Ther Drug Monit 6:277–283PubMedCrossRefGoogle Scholar
  52. Wilder BJ, Ramsay RE, Guterman A et al. (1986) A double-blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of Dainippon Pharmaceutical Co, LtdGoogle Scholar
  53. Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH (1985) Zonisamide in epilepsy: a pilot study. Epilepsia 26:212–220PubMedCrossRefGoogle Scholar
  54. Yagi K, Seino M (1992) Open clinical trial of new antiepileptic drug, zonisamide (ZNA) on 49 patients with refractory epileptic seizures. Clin Psychiat 29:111–119 (in Japanese)Google Scholar
  55. Yamatogi Y, Ohtahara S (1991) Current topics of treatment. In: Ohtahara S, Roger J (eds). Proceedings of the international symposium, new trends in pediatric epileptology. Okayama University Medical School, pp. 136–148Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • I. E. Leppik

There are no affiliations available

Personalised recommendations